Price movement over the last 24 hours
ADMA Biologics Inc vs Southern Copper Corp — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Southern Copper Corp trades at $166.52 (market cap $141.63B). The key difference: Southern Copper Corp is far larger — about 66.5× ADMA Biologics Inc's market cap, and Southern Copper Corp pays a 2.36% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SCCO | |
|---|---|---|
Market Cap | $2.13B | $141.63B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $218.85 |
52-Week Low | $7.60 | $90.54 |
Enterprise Value | $2.20B | $143.68B |
Dividend Yield | — | 2.36% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Southern Copper (SCCO) trades at $169.75, down 1.31% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 34.13% net income margin and robust earnings beats in recent quarters. Revenue growth accelerated to $13.42B in 2025, and the company maintains a solid cash flow profile with $4.75B from operations. Recent corporate actions include a $1.00 dividend and a minor stock split.
SCCO's outlook is supported by copper demand linked to AI infrastructure, but high valuation ratios (P/E 29.44) and bearish technicals pose risks. Analyst consensus is cautious with a $151.21 price target below the current price. Key risks include commodity price volatility and execution challenges in mining operations.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →